Berenberg Bank Issues Positive Forecast for AstraZeneca (LON:AZN) Stock Price

AstraZeneca (LON:AZN) had its price objective hoisted by stock analysts at Berenberg Bank from £145 to £160 in a research note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s target price would indicate a potential upside of 17.92% from the company’s previous close.

Several other equities analysts also recently weighed in on AZN. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Deutsche Bank Aktiengesellschaft upped their price objective on AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Jefferies Financial Group restated a “buy” rating and set a £150 price target on shares of AstraZeneca in a research report on Monday, November 10th. Citigroup started coverage on AstraZeneca in a research note on Tuesday. They issued a “buy” rating and a £170 target price on the stock. Finally, Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of £145.83.

AstraZeneca Price Performance

AZN traded down GBX 312 on Tuesday, hitting £135.68. 28,469,127 shares of the stock were exchanged, compared to its average volume of 69,461,414. The business has a 50-day moving average of £137.69 and a two-hundred day moving average of £125.53. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. AstraZeneca has a 12 month low of GBX 9,573.51 and a 12 month high of £144.10. The firm has a market capitalization of £210.34 billion, a price-to-earnings ratio of 22.54, a PEG ratio of 0.86 and a beta of 0.17.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of AstraZeneca stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is currently owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.